Last reviewed · How we verify
NCT07253272
A PET Study of ENX-104 in Healthy Volunteers
Phase 1 trial testing ENX-104 in Healthy Volunteers in 10 participants. Completed in 2 September 2025.
2 September 2025
Quick facts
| Lead sponsor | Engrail Therapeutics INC |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | other |
| Enrollment | 10 |
| Start date | 24 February 2025 |
| Primary completion | 2 September 2025 |
| Estimated completion | 2 September 2025 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- ENX-104 — full drug profile →
Conditions studied
- Healthy Volunteers — all drugs for Healthy Volunteers →
Sponsor
Engrail Therapeutics INC — full company profile →
Who can join
Adults 23 to 65, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is designed to evaluate the D2/D3 receptor occupancy (RO), safety, tolerability, and pharmacokinetics (PK) of ENX-104 in healthy volunteers.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07253272
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ENX-104
Trials testing the same drug.
- NCT07253324 — ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD) · Phase 1 · completed
Other recruiting trials for Healthy Volunteers
Currently open trials in the same condition.
- NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
- NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
- NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
- NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
- NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting
Other Engrail Therapeutics INC trials
Trials by the same sponsor.
- NCT07193563 — A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder · Phase 2 · completed
- NCT07253324 — ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD) · Phase 1 · completed
- NCT06653296 — A Dose-Response Safety Study of ENX-102 in Patients With GAD · Phase 2 · completed
- NCT05749055 — ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07253272 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Engrail Therapeutics INC
- Last refreshed: 28 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07253272.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing